Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

.

Teva Pharmaceutical Industries

(

TEVA

) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.6%. By the end of trading, Teva Pharmaceutical Industries fell 64 cents (-1.6%) to $39.56 on light volume. Throughout the day, 2.4 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.6 million shares. The stock ranged in price between $39.55-$39.94 after having opened the day at $39.87 as compared to the previous trading day's close of $40.20. Other companies within the Health Care sector that declined today were:

MEI Pharma

(

MEIP

), down 16.6%,

Hemispherx Biopharma

(

HEB

), down 10.5%,

Edap TMS

(

EDAP

), down 10%, and

Cadence Pharmaceuticals

(

CADX

), down 9.9%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $34.86 billion and is part of the

drugs

industry. The company has a P/E ratio of 10.9, below the average drugs industry P/E ratio of 11.2 and below the S&P 500 P/E ratio of 17.7. Shares are down 0.5% year to date as of the close of trading on Wednesday. Currently there are 18 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and nine rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, attractive valuation levels and expanding profit margins. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now

.

null